nodes	percent_of_prediction	percent_of_DWPC	metapath
Sumatriptan—ABCG2—Teniposide—lymphatic system cancer	0.18	0.266	CbGbCtD
Sumatriptan—ABCG2—Mitoxantrone—lymphatic system cancer	0.126	0.186	CbGbCtD
Sumatriptan—ABCG2—Vincristine—lymphatic system cancer	0.0866	0.128	CbGbCtD
Sumatriptan—SLCO1A2—Methotrexate—lymphatic system cancer	0.0699	0.103	CbGbCtD
Sumatriptan—SLCO1B1—Methotrexate—lymphatic system cancer	0.066	0.0976	CbGbCtD
Sumatriptan—ABCG2—Methotrexate—lymphatic system cancer	0.0524	0.0775	CbGbCtD
Sumatriptan—ABCB1—Mitoxantrone—lymphatic system cancer	0.0454	0.0671	CbGbCtD
Sumatriptan—ABCB1—Vincristine—lymphatic system cancer	0.0312	0.0462	CbGbCtD
Sumatriptan—ABCB1—Methotrexate—lymphatic system cancer	0.0189	0.028	CbGbCtD
Sumatriptan—Hypersensitivity—Teniposide—lymphatic system cancer	0.000403	0.00124	CcSEcCtD
Sumatriptan—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000403	0.00124	CcSEcCtD
Sumatriptan—Flushing—Carmustine—lymphatic system cancer	0.000402	0.00124	CcSEcCtD
Sumatriptan—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000401	0.00124	CcSEcCtD
Sumatriptan—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.0004	0.00123	CcSEcCtD
Sumatriptan—Anaemia—Bleomycin—lymphatic system cancer	0.000399	0.00123	CcSEcCtD
Sumatriptan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000396	0.00122	CcSEcCtD
Sumatriptan—Asthenia—Teniposide—lymphatic system cancer	0.000393	0.00121	CcSEcCtD
Sumatriptan—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00039	0.0012	CcSEcCtD
Sumatriptan—Melaena—Methotrexate—lymphatic system cancer	0.00039	0.0012	CcSEcCtD
Sumatriptan—Malaise—Bleomycin—lymphatic system cancer	0.00039	0.0012	CcSEcCtD
Sumatriptan—Pruritus—Teniposide—lymphatic system cancer	0.000387	0.0012	CcSEcCtD
Sumatriptan—Arrhythmia—Carmustine—lymphatic system cancer	0.000387	0.00119	CcSEcCtD
Sumatriptan—Cystitis—Methotrexate—lymphatic system cancer	0.000386	0.00119	CcSEcCtD
Sumatriptan—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000382	0.00118	CcSEcCtD
Sumatriptan—Body temperature increased—Fludarabine—lymphatic system cancer	0.00038	0.00117	CcSEcCtD
Sumatriptan—Erythema—Carmustine—lymphatic system cancer	0.000377	0.00116	CcSEcCtD
Sumatriptan—Cough—Bleomycin—lymphatic system cancer	0.000377	0.00116	CcSEcCtD
Sumatriptan—Angiopathy—Vincristine—lymphatic system cancer	0.000375	0.00116	CcSEcCtD
Sumatriptan—Diarrhoea—Teniposide—lymphatic system cancer	0.000374	0.00116	CcSEcCtD
Sumatriptan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000373	0.00115	CcSEcCtD
Sumatriptan—Chest pain—Bleomycin—lymphatic system cancer	0.000368	0.00114	CcSEcCtD
Sumatriptan—Myalgia—Bleomycin—lymphatic system cancer	0.000368	0.00114	CcSEcCtD
Sumatriptan—Back pain—Carmustine—lymphatic system cancer	0.000365	0.00113	CcSEcCtD
Sumatriptan—Discomfort—Bleomycin—lymphatic system cancer	0.000363	0.00112	CcSEcCtD
Sumatriptan—Chills—Mitoxantrone—lymphatic system cancer	0.000361	0.00112	CcSEcCtD
Sumatriptan—Bladder pain—Methotrexate—lymphatic system cancer	0.000361	0.00112	CcSEcCtD
Sumatriptan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00036	0.00111	CcSEcCtD
Sumatriptan—Confusional state—Bleomycin—lymphatic system cancer	0.000356	0.0011	CcSEcCtD
Sumatriptan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000354	0.00109	CcSEcCtD
Sumatriptan—Tremor—Carmustine—lymphatic system cancer	0.000353	0.00109	CcSEcCtD
Sumatriptan—Oedema—Bleomycin—lymphatic system cancer	0.000353	0.00109	CcSEcCtD
Sumatriptan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000353	0.00109	CcSEcCtD
Sumatriptan—Erythema—Mitoxantrone—lymphatic system cancer	0.000351	0.00108	CcSEcCtD
Sumatriptan—Infection—Bleomycin—lymphatic system cancer	0.00035	0.00108	CcSEcCtD
Sumatriptan—Anaemia—Carmustine—lymphatic system cancer	0.000349	0.00108	CcSEcCtD
Sumatriptan—Back pain—Vincristine—lymphatic system cancer	0.000348	0.00108	CcSEcCtD
Sumatriptan—Vomiting—Teniposide—lymphatic system cancer	0.000348	0.00107	CcSEcCtD
Sumatriptan—Agitation—Carmustine—lymphatic system cancer	0.000347	0.00107	CcSEcCtD
Sumatriptan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000345	0.00107	CcSEcCtD
Sumatriptan—Asthenia—Fludarabine—lymphatic system cancer	0.000345	0.00107	CcSEcCtD
Sumatriptan—Rash—Teniposide—lymphatic system cancer	0.000345	0.00107	CcSEcCtD
Sumatriptan—Dermatitis—Teniposide—lymphatic system cancer	0.000345	0.00106	CcSEcCtD
Sumatriptan—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000343	0.00106	CcSEcCtD
Sumatriptan—Headache—Teniposide—lymphatic system cancer	0.000343	0.00106	CcSEcCtD
Sumatriptan—Pruritus—Fludarabine—lymphatic system cancer	0.00034	0.00105	CcSEcCtD
Sumatriptan—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00034	0.00105	CcSEcCtD
Sumatriptan—Back pain—Mitoxantrone—lymphatic system cancer	0.000339	0.00105	CcSEcCtD
Sumatriptan—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000335	0.00103	CcSEcCtD
Sumatriptan—Anaemia—Vincristine—lymphatic system cancer	0.000333	0.00103	CcSEcCtD
Sumatriptan—Agitation—Vincristine—lymphatic system cancer	0.000331	0.00102	CcSEcCtD
Sumatriptan—Photosensitivity—Methotrexate—lymphatic system cancer	0.00033	0.00102	CcSEcCtD
Sumatriptan—Hypotension—Bleomycin—lymphatic system cancer	0.00033	0.00102	CcSEcCtD
Sumatriptan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000329	0.00102	CcSEcCtD
Sumatriptan—Convulsion—Carmustine—lymphatic system cancer	0.000327	0.00101	CcSEcCtD
Sumatriptan—Hypertension—Carmustine—lymphatic system cancer	0.000326	0.00101	CcSEcCtD
Sumatriptan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000325	0.001	CcSEcCtD
Sumatriptan—Nausea—Teniposide—lymphatic system cancer	0.000325	0.001	CcSEcCtD
Sumatriptan—Anaemia—Mitoxantrone—lymphatic system cancer	0.000324	0.001	CcSEcCtD
Sumatriptan—Vertigo—Vincristine—lymphatic system cancer	0.000323	0.000999	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000321	0.000992	CcSEcCtD
Sumatriptan—Myalgia—Carmustine—lymphatic system cancer	0.000321	0.000991	CcSEcCtD
Sumatriptan—Chest pain—Carmustine—lymphatic system cancer	0.000321	0.000991	CcSEcCtD
Sumatriptan—Anxiety—Carmustine—lymphatic system cancer	0.00032	0.000988	CcSEcCtD
Sumatriptan—Paraesthesia—Bleomycin—lymphatic system cancer	0.000317	0.000977	CcSEcCtD
Sumatriptan—Malaise—Mitoxantrone—lymphatic system cancer	0.000316	0.000976	CcSEcCtD
Sumatriptan—Dyspnoea—Bleomycin—lymphatic system cancer	0.000314	0.00097	CcSEcCtD
Sumatriptan—Renal failure acute—Methotrexate—lymphatic system cancer	0.000314	0.00097	CcSEcCtD
Sumatriptan—Convulsion—Vincristine—lymphatic system cancer	0.000312	0.000963	CcSEcCtD
Sumatriptan—Hypertension—Vincristine—lymphatic system cancer	0.000311	0.00096	CcSEcCtD
Sumatriptan—Confusional state—Carmustine—lymphatic system cancer	0.00031	0.000958	CcSEcCtD
Sumatriptan—Oedema—Carmustine—lymphatic system cancer	0.000308	0.00095	CcSEcCtD
Sumatriptan—Decreased appetite—Bleomycin—lymphatic system cancer	0.000307	0.000946	CcSEcCtD
Sumatriptan—Myalgia—Vincristine—lymphatic system cancer	0.000307	0.000946	CcSEcCtD
Sumatriptan—Visual disturbance—Methotrexate—lymphatic system cancer	0.000306	0.000945	CcSEcCtD
Sumatriptan—Cough—Mitoxantrone—lymphatic system cancer	0.000306	0.000944	CcSEcCtD
Sumatriptan—Infection—Carmustine—lymphatic system cancer	0.000306	0.000944	CcSEcCtD
Sumatriptan—Vomiting—Fludarabine—lymphatic system cancer	0.000306	0.000944	CcSEcCtD
Sumatriptan—Convulsion—Mitoxantrone—lymphatic system cancer	0.000304	0.000938	CcSEcCtD
Sumatriptan—Rash—Fludarabine—lymphatic system cancer	0.000303	0.000936	CcSEcCtD
Sumatriptan—Dermatitis—Fludarabine—lymphatic system cancer	0.000303	0.000935	CcSEcCtD
Sumatriptan—Hypertension—Mitoxantrone—lymphatic system cancer	0.000303	0.000934	CcSEcCtD
Sumatriptan—Pain—Bleomycin—lymphatic system cancer	0.000302	0.000931	CcSEcCtD
Sumatriptan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000301	0.00093	CcSEcCtD
Sumatriptan—Headache—Fludarabine—lymphatic system cancer	0.000301	0.00093	CcSEcCtD
Sumatriptan—Tachycardia—Carmustine—lymphatic system cancer	0.0003	0.000927	CcSEcCtD
Sumatriptan—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.0003	0.000925	CcSEcCtD
Sumatriptan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000299	0.000921	CcSEcCtD
Sumatriptan—Chest pain—Mitoxantrone—lymphatic system cancer	0.000299	0.000921	CcSEcCtD
Sumatriptan—Myalgia—Mitoxantrone—lymphatic system cancer	0.000299	0.000921	CcSEcCtD
Sumatriptan—Anxiety—Mitoxantrone—lymphatic system cancer	0.000297	0.000918	CcSEcCtD
Sumatriptan—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000296	0.000914	CcSEcCtD
Sumatriptan—Discomfort—Mitoxantrone—lymphatic system cancer	0.000295	0.00091	CcSEcCtD
Sumatriptan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000294	0.000907	CcSEcCtD
Sumatriptan—Oedema—Vincristine—lymphatic system cancer	0.000294	0.000907	CcSEcCtD
Sumatriptan—Infection—Vincristine—lymphatic system cancer	0.000292	0.000901	CcSEcCtD
Sumatriptan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000291	0.000897	CcSEcCtD
Sumatriptan—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00029	0.000895	CcSEcCtD
Sumatriptan—Confusional state—Mitoxantrone—lymphatic system cancer	0.000289	0.000891	CcSEcCtD
Sumatriptan—Nervous system disorder—Vincristine—lymphatic system cancer	0.000288	0.00089	CcSEcCtD
Sumatriptan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000288	0.000888	CcSEcCtD
Sumatriptan—Hypotension—Carmustine—lymphatic system cancer	0.000288	0.000888	CcSEcCtD
Sumatriptan—Oedema—Mitoxantrone—lymphatic system cancer	0.000286	0.000883	CcSEcCtD
Sumatriptan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000286	0.000883	CcSEcCtD
Sumatriptan—Nausea—Fludarabine—lymphatic system cancer	0.000286	0.000882	CcSEcCtD
Sumatriptan—Infection—Mitoxantrone—lymphatic system cancer	0.000284	0.000878	CcSEcCtD
Sumatriptan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000284	0.000877	CcSEcCtD
Sumatriptan—Shock—Mitoxantrone—lymphatic system cancer	0.000282	0.000869	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00028	0.000866	CcSEcCtD
Sumatriptan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00028	0.000865	CcSEcCtD
Sumatriptan—Urticaria—Bleomycin—lymphatic system cancer	0.00028	0.000865	CcSEcCtD
Sumatriptan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000279	0.000862	CcSEcCtD
Sumatriptan—Body temperature increased—Bleomycin—lymphatic system cancer	0.000279	0.000861	CcSEcCtD
Sumatriptan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000278	0.000858	CcSEcCtD
Sumatriptan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000277	0.000854	CcSEcCtD
Sumatriptan—Paraesthesia—Carmustine—lymphatic system cancer	0.000276	0.000853	CcSEcCtD
Sumatriptan—Hypotension—Vincristine—lymphatic system cancer	0.000275	0.000848	CcSEcCtD
Sumatriptan—Dyspnoea—Carmustine—lymphatic system cancer	0.000274	0.000847	CcSEcCtD
Sumatriptan—Somnolence—Carmustine—lymphatic system cancer	0.000274	0.000845	CcSEcCtD
Sumatriptan—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000268	0.000827	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000268	0.000826	CcSEcCtD
Sumatriptan—Decreased appetite—Carmustine—lymphatic system cancer	0.000268	0.000826	CcSEcCtD
Sumatriptan—Hypotension—Mitoxantrone—lymphatic system cancer	0.000267	0.000825	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000266	0.00082	CcSEcCtD
Sumatriptan—Paraesthesia—Vincristine—lymphatic system cancer	0.000264	0.000814	CcSEcCtD
Sumatriptan—Constipation—Carmustine—lymphatic system cancer	0.000263	0.000813	CcSEcCtD
Sumatriptan—Pain—Carmustine—lymphatic system cancer	0.000263	0.000813	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000261	0.000805	CcSEcCtD
Sumatriptan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00026	0.000802	CcSEcCtD
Sumatriptan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000257	0.000793	CcSEcCtD
Sumatriptan—Decreased appetite—Vincristine—lymphatic system cancer	0.000255	0.000788	CcSEcCtD
Sumatriptan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000255	0.000788	CcSEcCtD
Sumatriptan—Somnolence—Mitoxantrone—lymphatic system cancer	0.000254	0.000785	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000254	0.000783	CcSEcCtD
Sumatriptan—Feeling abnormal—Carmustine—lymphatic system cancer	0.000254	0.000783	CcSEcCtD
Sumatriptan—Fatigue—Vincristine—lymphatic system cancer	0.000253	0.000782	CcSEcCtD
Sumatriptan—Asthenia—Bleomycin—lymphatic system cancer	0.000253	0.000781	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000252	0.000777	CcSEcCtD
Sumatriptan—Pain—Vincristine—lymphatic system cancer	0.000251	0.000776	CcSEcCtD
Sumatriptan—Constipation—Vincristine—lymphatic system cancer	0.000251	0.000776	CcSEcCtD
Sumatriptan—Asthma—Methotrexate—lymphatic system cancer	0.000251	0.000774	CcSEcCtD
Sumatriptan—Pruritus—Bleomycin—lymphatic system cancer	0.000249	0.00077	CcSEcCtD
Sumatriptan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000249	0.000768	CcSEcCtD
Sumatriptan—Fatigue—Mitoxantrone—lymphatic system cancer	0.000247	0.000762	CcSEcCtD
Sumatriptan—Pancreatitis—Methotrexate—lymphatic system cancer	0.000246	0.000759	CcSEcCtD
Sumatriptan—Pain—Mitoxantrone—lymphatic system cancer	0.000245	0.000755	CcSEcCtD
Sumatriptan—Constipation—Mitoxantrone—lymphatic system cancer	0.000245	0.000755	CcSEcCtD
Sumatriptan—Body temperature increased—Carmustine—lymphatic system cancer	0.000243	0.000751	CcSEcCtD
Sumatriptan—Abdominal pain—Carmustine—lymphatic system cancer	0.000243	0.000751	CcSEcCtD
Sumatriptan—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00024	0.000742	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00024	0.000742	CcSEcCtD
Sumatriptan—Pancytopenia—Methotrexate—lymphatic system cancer	0.000238	0.000735	CcSEcCtD
Sumatriptan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000236	0.000728	CcSEcCtD
Sumatriptan—Dysuria—Methotrexate—lymphatic system cancer	0.000234	0.000724	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000234	0.000722	CcSEcCtD
Sumatriptan—Abdominal pain—Vincristine—lymphatic system cancer	0.000232	0.000717	CcSEcCtD
Sumatriptan—Body temperature increased—Vincristine—lymphatic system cancer	0.000232	0.000717	CcSEcCtD
Sumatriptan—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000229	0.000706	CcSEcCtD
Sumatriptan—Urticaria—Mitoxantrone—lymphatic system cancer	0.000227	0.000702	CcSEcCtD
Sumatriptan—Hypersensitivity—Carmustine—lymphatic system cancer	0.000227	0.0007	CcSEcCtD
Sumatriptan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000226	0.000698	CcSEcCtD
Sumatriptan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000226	0.000698	CcSEcCtD
Sumatriptan—Vomiting—Bleomycin—lymphatic system cancer	0.000224	0.000692	CcSEcCtD
Sumatriptan—Drowsiness—Methotrexate—lymphatic system cancer	0.000224	0.00069	CcSEcCtD
Sumatriptan—Depression—Methotrexate—lymphatic system cancer	0.000223	0.000688	CcSEcCtD
Sumatriptan—Rash—Bleomycin—lymphatic system cancer	0.000222	0.000686	CcSEcCtD
Sumatriptan—Dermatitis—Bleomycin—lymphatic system cancer	0.000222	0.000686	CcSEcCtD
Sumatriptan—Asthenia—Carmustine—lymphatic system cancer	0.000221	0.000682	CcSEcCtD
Sumatriptan—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000217	0.000671	CcSEcCtD
Sumatriptan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000216	0.000668	CcSEcCtD
Sumatriptan—Sweating—Methotrexate—lymphatic system cancer	0.000214	0.000662	CcSEcCtD
Sumatriptan—Haematuria—Methotrexate—lymphatic system cancer	0.000213	0.000658	CcSEcCtD
Sumatriptan—Epistaxis—Methotrexate—lymphatic system cancer	0.000211	0.000651	CcSEcCtD
Sumatriptan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000211	0.000651	CcSEcCtD
Sumatriptan—Asthenia—Vincristine—lymphatic system cancer	0.000211	0.000651	CcSEcCtD
Sumatriptan—Diarrhoea—Carmustine—lymphatic system cancer	0.000211	0.00065	CcSEcCtD
Sumatriptan—Nausea—Bleomycin—lymphatic system cancer	0.000209	0.000647	CcSEcCtD
Sumatriptan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000205	0.000634	CcSEcCtD
Sumatriptan—Dizziness—Carmustine—lymphatic system cancer	0.000204	0.000628	CcSEcCtD
Sumatriptan—Haemoglobin—Methotrexate—lymphatic system cancer	0.000202	0.000623	CcSEcCtD
Sumatriptan—Diarrhoea—Vincristine—lymphatic system cancer	0.000201	0.000621	CcSEcCtD
Sumatriptan—Haemorrhage—Methotrexate—lymphatic system cancer	0.000201	0.000619	CcSEcCtD
Sumatriptan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000196	0.000604	CcSEcCtD
Sumatriptan—Vomiting—Carmustine—lymphatic system cancer	0.000196	0.000604	CcSEcCtD
Sumatriptan—Dizziness—Vincristine—lymphatic system cancer	0.000194	0.0006	CcSEcCtD
Sumatriptan—Rash—Carmustine—lymphatic system cancer	0.000194	0.000599	CcSEcCtD
Sumatriptan—Dermatitis—Carmustine—lymphatic system cancer	0.000194	0.000599	CcSEcCtD
Sumatriptan—Visual impairment—Methotrexate—lymphatic system cancer	0.000193	0.000597	CcSEcCtD
Sumatriptan—Headache—Carmustine—lymphatic system cancer	0.000193	0.000595	CcSEcCtD
Sumatriptan—Eye disorder—Methotrexate—lymphatic system cancer	0.000188	0.000579	CcSEcCtD
Sumatriptan—Tinnitus—Methotrexate—lymphatic system cancer	0.000187	0.000578	CcSEcCtD
Sumatriptan—Vomiting—Vincristine—lymphatic system cancer	0.000187	0.000577	CcSEcCtD
Sumatriptan—Rash—Vincristine—lymphatic system cancer	0.000185	0.000572	CcSEcCtD
Sumatriptan—Dermatitis—Vincristine—lymphatic system cancer	0.000185	0.000571	CcSEcCtD
Sumatriptan—Headache—Vincristine—lymphatic system cancer	0.000184	0.000568	CcSEcCtD
Sumatriptan—Nausea—Carmustine—lymphatic system cancer	0.000183	0.000564	CcSEcCtD
Sumatriptan—Angiopathy—Methotrexate—lymphatic system cancer	0.000182	0.000562	CcSEcCtD
Sumatriptan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000182	0.000562	CcSEcCtD
Sumatriptan—Immune system disorder—Methotrexate—lymphatic system cancer	0.000181	0.00056	CcSEcCtD
Sumatriptan—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000181	0.000558	CcSEcCtD
Sumatriptan—Rash—Mitoxantrone—lymphatic system cancer	0.00018	0.000557	CcSEcCtD
Sumatriptan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00018	0.000556	CcSEcCtD
Sumatriptan—Chills—Methotrexate—lymphatic system cancer	0.00018	0.000556	CcSEcCtD
Sumatriptan—Headache—Mitoxantrone—lymphatic system cancer	0.000179	0.000553	CcSEcCtD
Sumatriptan—Erythema—Methotrexate—lymphatic system cancer	0.000175	0.000539	CcSEcCtD
Sumatriptan—Nausea—Vincristine—lymphatic system cancer	0.000175	0.000539	CcSEcCtD
Sumatriptan—Dysgeusia—Methotrexate—lymphatic system cancer	0.000171	0.000528	CcSEcCtD
Sumatriptan—Nausea—Mitoxantrone—lymphatic system cancer	0.00017	0.000525	CcSEcCtD
Sumatriptan—Back pain—Methotrexate—lymphatic system cancer	0.000169	0.000522	CcSEcCtD
Sumatriptan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000162	0.0005	CcSEcCtD
Sumatriptan—Anaemia—Methotrexate—lymphatic system cancer	0.000161	0.000498	CcSEcCtD
Sumatriptan—Malaise—Methotrexate—lymphatic system cancer	0.000158	0.000486	CcSEcCtD
Sumatriptan—Vertigo—Methotrexate—lymphatic system cancer	0.000157	0.000484	CcSEcCtD
Sumatriptan—Cough—Methotrexate—lymphatic system cancer	0.000152	0.000471	CcSEcCtD
Sumatriptan—Convulsion—Methotrexate—lymphatic system cancer	0.000151	0.000467	CcSEcCtD
Sumatriptan—Myalgia—Methotrexate—lymphatic system cancer	0.000149	0.000459	CcSEcCtD
Sumatriptan—Arthralgia—Methotrexate—lymphatic system cancer	0.000149	0.000459	CcSEcCtD
Sumatriptan—Chest pain—Methotrexate—lymphatic system cancer	0.000149	0.000459	CcSEcCtD
Sumatriptan—Discomfort—Methotrexate—lymphatic system cancer	0.000147	0.000454	CcSEcCtD
Sumatriptan—Confusional state—Methotrexate—lymphatic system cancer	0.000144	0.000444	CcSEcCtD
Sumatriptan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000143	0.00044	CcSEcCtD
Sumatriptan—Infection—Methotrexate—lymphatic system cancer	0.000142	0.000437	CcSEcCtD
Sumatriptan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00014	0.000432	CcSEcCtD
Sumatriptan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00014	0.000431	CcSEcCtD
Sumatriptan—Skin disorder—Methotrexate—lymphatic system cancer	0.000138	0.000427	CcSEcCtD
Sumatriptan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000138	0.000425	CcSEcCtD
Sumatriptan—Hypotension—Methotrexate—lymphatic system cancer	0.000133	0.000411	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00013	0.000401	CcSEcCtD
Sumatriptan—Paraesthesia—Methotrexate—lymphatic system cancer	0.000128	0.000395	CcSEcCtD
Sumatriptan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000127	0.000392	CcSEcCtD
Sumatriptan—Somnolence—Methotrexate—lymphatic system cancer	0.000127	0.000391	CcSEcCtD
Sumatriptan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000124	0.000383	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000123	0.00038	CcSEcCtD
Sumatriptan—Fatigue—Methotrexate—lymphatic system cancer	0.000123	0.000379	CcSEcCtD
Sumatriptan—Pain—Methotrexate—lymphatic system cancer	0.000122	0.000376	CcSEcCtD
Sumatriptan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000117	0.000363	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000117	0.00036	CcSEcCtD
Sumatriptan—Urticaria—Methotrexate—lymphatic system cancer	0.000113	0.00035	CcSEcCtD
Sumatriptan—Abdominal pain—Methotrexate—lymphatic system cancer	0.000113	0.000348	CcSEcCtD
Sumatriptan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000113	0.000348	CcSEcCtD
Sumatriptan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000105	0.000324	CcSEcCtD
Sumatriptan—Asthenia—Methotrexate—lymphatic system cancer	0.000102	0.000316	CcSEcCtD
Sumatriptan—Pruritus—Methotrexate—lymphatic system cancer	0.000101	0.000311	CcSEcCtD
Sumatriptan—Diarrhoea—Methotrexate—lymphatic system cancer	9.76e-05	0.000301	CcSEcCtD
Sumatriptan—Dizziness—Methotrexate—lymphatic system cancer	9.43e-05	0.000291	CcSEcCtD
Sumatriptan—Vomiting—Methotrexate—lymphatic system cancer	9.07e-05	0.00028	CcSEcCtD
Sumatriptan—Rash—Methotrexate—lymphatic system cancer	8.99e-05	0.000277	CcSEcCtD
Sumatriptan—Dermatitis—Methotrexate—lymphatic system cancer	8.98e-05	0.000277	CcSEcCtD
Sumatriptan—Headache—Methotrexate—lymphatic system cancer	8.93e-05	0.000276	CcSEcCtD
Sumatriptan—Nausea—Methotrexate—lymphatic system cancer	8.47e-05	0.000261	CcSEcCtD
